> The main problem with the article is that all the vaccines are approved after a RCT were the vaccine is compared to a placebo The author talks about effectiv

> The main problem with the article is that all the vaccines are approved after a RCT were the vaccine is compared to a placebo The author talks about effectiveness wrt mortality rates. No statistically significant difference was found during RCTs: > During the blinded, controlled period, 15 BNT162b2 and 14 placebo recipients died https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.full.pdf+html https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v...